SCHEMBL25359136

SCHEMBL25359136

CC(C)CNCCNC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.62
CYP2D6 P10635 1/20 0.62
MMP1 P03956 1/20 0.39
MMP8 P22894 1/20 0.39
SCN1A P35498 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN3A Q9NY46 1/20 0.38
MAPT P10636 2/20 0.37
EPHX1 P07099 1/20 0.37
ANPEP P15144 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
ADH1B P00325 1/20 0.36
ADH1C P00326 1/20 0.36
ADH1A P07327 1/20 0.36
HPGD P15428 4/20 0.35
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3349299 0.87 CYP2D6 (0.58) CYP2C19CYP2D6MMP1MMP8SCN1A
SCHEMBL23200719 0.83 CYP2D6 (0.46) CYP2C19CYP2D6ANPEPALDH1A1USP2
SCHEMBL23200720 0.83 CYP2D6 (0.46) CYP2C19CYP2D6ANPEPALDH1A1USP2
SCHEMBL14471288 0.82 KDM4E (0.46) CYP2C19CYP2D6MMP1MMP8SCN1A
SCHEMBL14453859 0.80 CYP2C19 (0.43) CYP2C19CYP2D6MMP1MMP8SCN1A
SCHEMBL21322189 0.80 CYP2D6 (0.43) CYP2C19CYP2D6MMP1MMP8SCN1A
SCHEMBL402167 0.78
SCHEMBL2240590 0.77 CA3 (0.42) CYP2C19CYP2D6ALDH1A1KMT2AMEN1
SCHEMBL1005943 0.77 ADH1B (0.45) CYP2C19CYP2D6MMP1MMP8SCN1A
SCHEMBL3420003 0.77 CYP2C19 (0.40) CYP2C19CYP2D6MMP1MMP8SCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365587-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-11-16 US disclosed
EP-4225762-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365587-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B CYP2C19 4662/4885CYP2D6 4560/4885MMP1 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.